Basic Information |
|
| Product Name： | DROSPIRENONE |
| CAS： | 19457-55-7 ;67392-87-4 |
| English Synonyms： | DIHYDROSPIRORENONE ; DROSPERINONE ; 6B,7B:15B,16B-DIMETHYLEN-3-OXO-17A-PREGN-4-ENE-21,17-CARBOLACTONE ; 6BETA,7BETA,15BETA,16BETA-DIMETHYLENE-3-OXO-17ALPHA-PREGN-4-ENE-21,17-CARBOLACTONE ; DROSPIRENONE ; ANGELIQ ; DROSPIREONE |
| MDL Number.： | MFCD00867350 |
| H bond acceptor： | 3 |
| H bond donor： | 0 |
| Smile： | C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C |
| InChi： | InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1 |
| InChiKey： | InChIKey=METQSPRSQINEEU-HXCATZOESA-N |
Property |
|
| Comments： | BIOCHEM/PHYSIOL ACTIONS: DROSPIRENONE IS A FOURTH-GENERATION PROGESTIN THAT HAS ANTIMINERALOCORTICOID, AND ANTIANDROGENIC ACTIVITY IN ADDITION TO POTENT PROGESTOGENIC ACTIVITY. IN TWO RECENT STUDIES DROSPIRENONE APPEARED TO DOUBLE THE RISK OF VENOUS THROMBOEMBOLISM COMPARED TO LEVONORGESTREL, ALTHOUGH OTHER STUDIES FOUND LITTLE ADDED RISK GENERAL DESCRIPTION: THIS PRODUCT IS PROVIDED AS DELIVERED AND SPECIFIED BY THE ISSUING PHARMACOPOEIA. ALL INFORMATION PROVIDED IN SUPPORT OF THIS PRODUCT, INCLUDING MSDS AND ANY PRODUCT INFORMATION LEAFLETS HAVE BEEN DEVELOPED AND ISSUED UNDER THE AUTHORITY OF THE ISSUING PHARMACOPOEIA. FOR FURTHER INFORMATION AND SUPPORT PLEASE GO TO THE WEBSITE OF THE ISSUING PHARMACOPOEIA OTHER NOTES: SALES RESTRICTIONS MAY APPLY |
Safety information |
|
| Symbol： |
GHS08
|
| Signal word： | Danger |
| Hazard statements： | H360 |
| Precautionary statements： | P201-P308 + P313 |
| hazard symbol： | T |
| Risk Code： | R:60 |
| Safe Code： | S:36/37 |
| WGK Germany： | 3 |
* If the product has intellectual property rights, a license granted is must or contact us.
2010-2025 © Chemical Cloud Database. ALL Rights Reserved.浙ICP备11020424号-1
浙公网安备 33010802004002号
中文版